Nexstim Plc (HEL:NXTMH)
9.64
-0.21 (-2.13%)
Jul 28, 2026, 11:15 AM EET
Nexstim Revenue
In the year 2025, Nexstim had annual revenue of 12.42M EUR with 20.72% growth. Nexstim had revenue of 7.05M in the half year ending December 31, 2025, with 30.18% growth.
Revenue
12.42M
Revenue Growth
+20.72%
P/S Ratio
6.41
Revenue / Employee
310.33K
Employees
40
Market Cap
79.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.42M | 2.13M | 20.72% |
| Dec 31, 2024 | 10.29M | 1.69M | 19.68% |
| Dec 31, 2023 | 8.60M | -2.20M | -20.38% |
| Dec 31, 2022 | 10.80M | 3.24M | 42.85% |
| Dec 31, 2021 | 7.56M | 3.39M | 81.25% |
| Dec 31, 2020 | 4.17M | 758.89K | 22.25% |
| Dec 31, 2019 | 3.41M | 668.90K | 24.39% |
| Dec 31, 2018 | 2.74M | -12.12K | -0.44% |
| Dec 31, 2017 | 2.75M | 228.55K | 9.05% |
| Dec 31, 2016 | 2.53M | -124.09K | -4.68% |
| Dec 31, 2015 | 2.65M | 274.92K | 11.58% |
| Dec 31, 2014 | 2.37M | 395.60K | 19.99% |
| Dec 31, 2013 | 1.98M | -1.73M | -46.67% |
| Dec 31, 2012 | 3.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orion Oyj | 2.06B |
| Oriola Oyj | 1.91B |
| Terveystalo Oyj | 1.21B |
| Pihlajalinna Oyj | 571.73M |
| Revenio Group Oyj | 111.05M |
| Biohit Oyj | 15.73M |
| Modulight Oyj | 10.43M |
| Nanoform Finland Oyj | 5.42M |
Nexstim News
- 5 months ago - Nexstim Earnings Call Transcript: H2 2025 - Transcripts
- 5 months ago - Nexstim Annual report: H2 2025 - Filings
- 5 months ago - Nexstim Quarterly report: H2 2025 - Filings
- 5 months ago - Nexstim Slides: H2 2025 - Filings
- 5 months ago - Nexstim Quarterly report: H2 2025 - Filings
- 5 months ago - Nexstim Slides: H2 2025 - Filings
- 9 months ago - Nexstim Transcript: Life Science Summit 2025 - Transcripts
- 1 year ago - Nexstim Earnings Call Transcript: H1 2025 - Transcripts